CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 11.48: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
2.52BCNY375.06M · vs all stocks (USD)
Revenue (TTM)
209.51MCNY31.16M · vs all stocks (USD)
Profit Margin
-47.74%vs Biotechnology peers
Beta
0.7620xvs all stocks
52-Week Change
-8.94%vs all stocks
Market Capitalization
2.52BCNY375.06M · vs all stocks (USD)
Enterprise Value
1.81BCNY268.70M · vs all stocks (USD)
Price to Sales (TTM)
12.04xvs Biotechnology peers
Price to Book (MRQ)
1.84xvs Biotechnology peers
Enterprise to Revenue
8.62xvs Biotechnology peers
Enterprise to EBITDA
-20.03xvs Biotechnology peers
Gross Margin
47.18%vs Biotechnology peers
Profit Margin
-47.74%vs Biotechnology peers
Operating Margin
-31.97%vs Biotechnology peers
Return on Assets (TTM)
-4.92%vs Biotechnology peers
Return on Equity (TTM)
-7.42%vs Biotechnology peers
Revenue (TTM)
209.51MCNY31.16M · vs all stocks (USD)
Revenue per Share (TTM)
1.91CNYUpdated Aug 21, 2026Quarterly Revenue Growth
37.20%vs Biotechnology peers
Gross Profit (TTM)
89.43MCNY13.30M · vs all stocks (USD)
EBITDA (TTM)
-90.20MCNY-13.41M · vs all stocks (USD)
Net Income (TTM)
-100.02MCNY-14.87M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
113.82%vs Biotechnology peers
Operating Cash Flow (TTM)
-74.66MCNY-11.10M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-77.39MCNY-11.51M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
7.18MCNYFY2025 · Dec 31, 2025Revenue
193.52MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
105.65MCNYFY2025 · Dec 31, 2025Gross Profit
87.87MCNYFY2025 · Dec 31, 2025Operating Income
-120.36MCNY-17.90M · vs all stocks (USD)
Pre-tax Income
-106.56MCNYFY2025 · Dec 31, 2025Income Tax Expense
4.77MCNYFY2025 · Dec 31, 2025Net Income
-111.33MCNYFY2025 · Dec 31, 2025EBIT
-105.59MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-74.07MCNYFY2025 · Dec 31, 2025Research & Development
77.37MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
22.82MCNYFY2025 · Dec 31, 2025Other Operating Expenses
2.34MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.44MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
966.06KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.9770CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.9770CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
109.94MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
109.94MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-111.33MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
3.92MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-122.10MCNYFY2025 · Dec 31, 2025Free Cash Flow
-156.39MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
161.27MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-111.33MCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.02MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-14.60MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-196.51KCNYFY2025 · Dec 31, 2025Capital Expenditures
-34.29MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.49BCNYFY2025 · Dec 31, 2025Sale of Investments
1.53BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
3.58MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
4.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-6.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-257.44KCNYFY2025 · Dec 31, 2025Other Financing Charges
-35.63MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-37.88MCNYFY2025 · Dec 31, 2025Shares Outstanding
112.49MSharesUpdated Aug 21, 2026Float Shares
34.97MSharesUpdated Aug 21, 2026% Held by Insiders
68.85%vs all stocks
% Held by Institutions
5.35%vs all stocks
Total Cash (MRQ)
724.54MCNY107.75M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.59CNYUpdated Aug 21, 2026Total Debt (MRQ)
10.33MCNY1.54M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0077xvs Biotechnology peers
Current Ratio (MRQ)
13.76xvs Biotechnology peers
Book Value per Share (MRQ)
12.17CNYUpdated Aug 21, 2026Total Assets
1.50BCNY222.58M · vs all stocks (USD)
Total Current Assets
1.03BCNYFY2025 · Dec 31, 2025Total Liabilities
138.47MCNYFY2025 · Dec 31, 2025Total Non-current Assets
463.33MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
64.40MCNYFY2025 · Dec 31, 2025Total Current Liabilities
74.07MCNYFY2025 · Dec 31, 2025Cash
161.28MCNYFY2025 · Dec 31, 2025Cash Equivalents
71.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
161.28MCNYFY2025 · Dec 31, 2025Other Short-term Investments
420.14MCNYFY2025 · Dec 31, 2025Accounts Receivable
58.78MCNYFY2025 · Dec 31, 2025Inventory
48.77MCNYFY2025 · Dec 31, 2025Accounts Payable
19.39MCNYFY2025 · Dec 31, 2025Short-term Debt
9.91MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.19MCNYFY2025 · Dec 31, 2025Long-term Debt
4.54MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
124.56KCNYFY2025 · Dec 31, 2025Common Stock (Book)
112.49MCNYFY2025 · Dec 31, 2025Retained Earnings
-123.84MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.36BCNY201.99M · vs all stocks (USD)
Treasury Stock
47.67MCNYFY2025 · Dec 31, 202552-Week Low
14.42CNYUpdated Aug 21, 202652-Week High
33.67CNYUpdated Aug 21, 202652-Week Change
-8.94%vs all stocks
Beta
0.7620xvs all stocks
50-Day MA
17.55CNYUpdated Aug 21, 2026200-Day MA
22.07CNYUpdated Aug 21, 2026Avg 10-Day Volume
2.35MSharesUpdated Aug 21, 2026Avg 30-Day Volume
1.70MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.9100CNYUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.37Receivables vs revenue divergence: 3.55
High gross margins eroded by operating costsNotable
Gross Margin: 0.47Profit Margin: -0.48
Financial Health
Altman Z-Score 11.48: safe zoneNotable
Altman Z-Score: 11.48
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Compass Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Province Xidian Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Upstream Bio, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Nanjing Xinjiekou Department Store Co. Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Halo Microelectronics Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Olaplex Holdings, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity